<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220313054269N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-05-24</date_registration>
      <primary_sponsor>Islamic Azad University, Science and Research Branch</primary_sponsor>
      <public_title>Effect of synbiotic in treatment of diabetes</public_title>
      <acronym></acronym>
      <scientific_title>The effect of combination therapy with insulin and synbiotic on platelet indices in children with type 1 diabetes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-28</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>76</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63186</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: To randomize the treatment between two groups, Permuted Block Randomization Method with the Size 4, will be used. Considering the time of patients entry into the study and that A is (Intervention group) and B is (Control group), A Part of the Random Allocation will be as follows:
Randomization is done with SAS software version 9.
Seed: 253569775886591 
Block sizes: 4 
Actual list length: 76 
block identifier, block size, sequence within block, treatment 
•	1, 4, 1, Group B
•	1, 4, 2, Group A
•	1, 4, 3, Group B
•	1, 4, 4, Group A
•	2, 4, 1, Group B
•	2, 4, 2, Group A
•	2, 4, 3, Group B
•	2, 4, 4, Group A
Groups assignment will be performed by the closed envelopes. The researcher registers the participants and the statistician determines the allocation sequence using the relevant softwares, Blinding description: In this double-blind, randomized, clinical trial, blinding will be performed for the researcher (outcome assessor) and the participants. The researcher (outcome assessor) doesn't know which participant is in the intervention or control group and the participants don't know which group they are in.</study_design>
      <phase>3</phase>
      <hc_freetext>Type 1 diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Synbiotic (Kidilact sachet of Zist-Takhmir company with the power of 10^9 CFU, containing Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, Bifidobacterium infantis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium lactis, Sterptococcus thermophilus Suchets and Fructooligosaccharide) is given to the intervention's group participants in the same 1 gram powder form sachets. Everyday, participants mix one sachet weighing 1 gram with 250ml water and drink it 15-20 mins before the evening meal. Intervention 2: Control group: Placebo (Product of Zist-Takhmir company, Containing Lactose monohydrate 80 Mesh, Inulin, Talc, Magnesium stearate, Colloidal silicon dioxide, Sucralose, Corn flour and Xanthan gum) is given to the intervention's group participants in the same 1 gram powder form sachets. Everyday, participants mix one sachet weighing 1 gram with 250ml water and drink it 15-20 mins before the evening meal.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Confidentiality of patients information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sara Sarrafizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Science and Research Branch, Daneshgah Square, Simon Bulivar Blvd, Ashrafi Esfahani Expy</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1477893855</zip>
        <telephone>+98 21 4486 7161</telephone>
        <email>sara.sarrafi@gmail.com</email>
        <affiliation>Islamic Azad University, Science and Research Branch</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Setila Dalili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>17 Shahrivar Educational, Therapeutic and Research Center, South of the City Park, Siadati Ave, Namjou Blvd</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4144654379</zip>
        <telephone>+98 13 3336 9019</telephone>
        <email>setiladalili1346@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Girls and Boys 4-18 Years
Being Treated with Injectable Insulin
Fasting Blood Sugar (FBS) ≥ 126 mg/dl
Glucose, 2 hour Post Prandial (2hpp) ≥ 200 mg/dl
Glycated Hemoglobin (HbA1c) ≥ 6.5%
Blood Sugar (BS) ≥ 200 mg/dl Along with Polydipsia and Polyuria</inclusion_criteria>
      <agemin>4 years</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Taking antibiotics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), immunosuppressants during the last month
Taking products containing probiotics and synbiotics in the last month
Metabolic disease
Gastrointestinal disease
Cardiovascular disease (CVD)
Renal disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E10.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 1 diabetes mellitus without complications</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Synbiotic (Kidilact sachet of Zist-Takhmir company with the power of 10^9 CFU, containing Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, Bifidobacterium infantis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium lactis, Sterptococcus thermophilus Suchets and Fructooligosaccharide) is given to the intervention's group participants in the same 1 gram powder form sachets. Everyday, participants mix one sachet weighing 1 gram with 250ml water and drink it 15-20 mins before the evening meal.</i_keyword>
      <i_keyword>Control group: Placebo (Product of Zist-Takhmir company, Containing Lactose monohydrate 80 Mesh, Inulin, Talc, Magnesium stearate, Colloidal silicon dioxide, Sucralose, Corn flour and Xanthan gum) is given to the intervention's group participants in the same 1 gram powder form sachets. Everyday, participants mix one sachet weighing 1 gram with 250ml water and drink it 15-20 mins before the evening meal.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood Platelet Count (PLT). Timepoint: Blood Platelet counting at the beginning of the intervention (Before the start of the intervention) and 12 weeks after the start of synbiotic and/or placebo usage. Method of measurement: Sysmex XS800 hematology analyzer.</prim_outcome>
      <prim_outcome>Platelet Percentage (PCT). Timepoint: Platelet Percentage calculating at the beginning of the intervention (Before the start of the intervention) and 12 weeks after the start of synbiotic and/or placebo usage. Method of measurement: Sysmex XS800 hematology analyzer.</prim_outcome>
      <prim_outcome>Mean Platelet Volume (MPV). Timepoint: Mean Platelet Volume calculating at the beginning of the intervention (Before the start of the intervention) and 12 weeks after the start of synbiotic and/or placebo usage. Method of measurement: Sysmex XS800 hematology analyzer.</prim_outcome>
      <prim_outcome>Platelet Distribution Width (PDW). Timepoint: Platelet Distribution Width calculating at the beginning of the intervention (Before the start of the intervention) and 12 weeks after the start of synbiotic and/or placebo usage. Method of measurement: Sysmex XS800 hematology analyzer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice-Chancellor for Research &amp; Technology, Islamic Azad University, Science and Research Branch</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-11-02</approval_date>
        <contact_name>Ethics committee of Islamic Azad University, Science and Research Branch</contact_name>
        <contact_address>Science and Research Branch, Daneshgah Square, Simon Bulivar Blvd, Ashrafi Esfahani Expy Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
